Benjamin Kleinstiver

Dr. Ben Kleinstiver received his doctoral degree from the Western University. He had completed postdoctoral research at the MGH and HMS. Dr. Ben Kleinstiver is currently a Assistant Investigator, Massachusetts General Hospital (MGH) and Assistant Professor, Harvard Medical School (HMS). They develop genome engineering technologies for research applications and for the treatment of human diseases. They have a deep interest in building, characterizing, and optimizing new genome editing technologies to further enable their wide application across a variety of scientific disciplines. A major goal of our lab is to learn about the challenges that face the effective clinical translation of genome editing technologies. Situated in the Center for Genomic Medicine at Massachusetts General Hospital, his group is collaborating with several other laboratories to leverage novel technologies to both create disease models, and to develop preclinical strategies to correct pathogenic sequences. They're pursuing these efforts with the hope that the promise of genome editing technologies can be realized for the treatment of human diseases.

Lab Information

The Kleinstiver Lab

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Genome Editing Technologies 0 Protein Engineering 0 Molecular Medicines 0


  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)

This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More

This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More

IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More

"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More

In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More

The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More

This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More

The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More

The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More

  1. Hille LT, Kleinstiver BP. (2021) Plant genome editing branches out. Nature Plants; doi: 10.1038/s41477-020-00840-7, online ahead of print

  2. Neggers JE, Jacquemyn M, Dierckx T, Kleinstiver BP, Thibaut HJ, Daelemans D. (2020) enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. Molecular Therapy; doi: 10.1016/j.ymthe.2020.09.025, online ahead of print

  3. Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. (2020) Cell-based artificial APCs resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal for ImmunoTherapy of Cancer; doi: 10.1136/jitc-2020-000990, online ahead of print

  4. DeWeirdt PC, Sanson KR, Sangree AK, Murda H, Hanna RE, Feeley MN, Griffith AL, Teng T, Borys SM, Strand C, Joung JK, Kleinstiver BP, Pan X, Huang A, Doench JG. (2020) Optimization of AsCas12a for combinatorial genetic screens in human cells. Nature Biotechnology; doi: 10.1038/s41587-020-0600-6, online ahead of print

  5. Cruz L, György B, Cheah PS, Kleinstiver BP, Eimer WA, Garcia SP, Sharma N, Ozelius LJ, Bragg DC, Joung JK, Norberto de Souza O, Macedo Timmers LFS, Breakefield XO. (2020) Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. Molecular Therapy Nucleic Acids; 15(21):1-12

  6. Osuna BA, Karambelkar S, Mahendra C, Christie KA, Garcia B, Davidson AR, Kleinstiver BP, Kilcher S, Bondy-Denomy J. (2020) Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes. Cell Host Microbe; S1931-3128(20):30190-6

  7. Walton RT, Christie KA, Whittaker MN, Kleinstiver BP. (2020) Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants. Science; 368(6488):290-6

  8. Mahendra C, Christie KA, Osuna BA, Pinilla-Redondo R, Kleinstiver BP, Bondy-Denomy J. (2020) Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer. Nature Microbiology; 5(4):620-629

  9. Breuer CB, Hanlon KS, Natasan JS, Volak A, Meliani A, Mingozzi F, Kleinstiver BP, Moon JJ, Maguire CA. (2020) In Vivo Engineering of Lymphocytes After Systemic Exosome-Associated AAV Delivery. Scientific Reports; 11;10(1):4544

  10. Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski SP, Volak A, Spirig SE, Muller A, Sousa AA, Tsai SQ, Bengtsson NE, Lööv C, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, Joung JK, Breakefield XO, Maguire CA, György B. (2019) High Levels of AAV Vector Integration Into CRISPR-induced DNA Breaks. Nature Communications; 10(1):4439-4449

  11. Anikeeva P, Boyden E, Brangwynne C, Cissé II, Fiehn O, Fromme P, Gingras AC, Greene CS, Heard E, Hell SW, Hillman E, Jensen GJ, Karchin R, Kiessling LL, Kleinstiver BP, Knight R, Kukura P, Lancaster MA, Loman N, Looger L, Lundberg E, Luo Q, Miyawaki A, Myers EW Jr, Nolan GP, Picotti P, Reik W, Sauer M, Shalek AK, Shendure J, Slavov N, Tanay A, Troyanskaya O, van Valen D, Wang HW, Yi C, Yin P, Zernicka-Goetz M, Zhuang. (2019) Voices in Method Development. Nature Methods; 16(10):945–951

  12. György B, Nist-Lund C, Pan B, Asai Y, Karavitaki KD, Kleinstiver BP, Garcia SP, Zaborowski MP, Solanes P, Spataro S, Schneider BL, Joung JK, Géléoc GSG, Holt JR, Corey DP. (2019) Allele-specific Gene Editing Prevents Deafness in a Model of Dominant Progressive Hearing Loss. Nature Medicine; 25(7):1123-1130

  13. Kleinstiver BP**, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK**. (2019) Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nature Biotechnology; 37(3):276-282

  14. **co-corresponding authors

  15. Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, Walton RT, Berry JD, Joung JK, Kleinstiver BP, Bondy-Denomy J. (2018) Discovery of widespread type I and type V CRISPR-Cas inhibitors. Science; 362(6411):240-24

  16. Lee K, Zhang Y, Kleinstiver BP, Guo JA, Aryee MJ, Miller J, Malzahn A, Zarecor S, Lawrence-Dill CJ, Joung JK, Qi Y, Wang K. (2019) Activities and specificities of CRISPR/Cas9 and Cas12a nucleases for targeted mutagenesis in maize. Plant Biotechnology Journal; 17(2):362-372

  17. György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, Ingelsson M. (2018) CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease. Molecular Therapy Nucleic Acids; 11:429-440

  18. Chowdhury TA, Koceja C, Eisa-Beygi S, Kleinstiver BP, Ku Kumar SN, Lin CW, Li K, Prabhudesai S, Joung JK, Ramchandran R. (2018) Temporal and Spatial Post-Transcriptional Regulation of Zebrafish tie1 mRNA by Long Noncoding RNA During Brain Vascular Assembly. Arteri. Thromb. Vasc. Biol.; 38(7):1562-1575

  19. Li P, Kleinstiver BP, Leon MY, Prew MS, Nararro-Gomez D, Greenwald SH, Pierce EA, Joung JK, Liu Q. (2018) Allele-specific editing of rhodopsin P23H knock-in mice broadens therapeutic potential of CRISPR/Cas for dominant genetic diseases. The CRISPR Journal; 1(1):55-64

  20. Listgarten J, Weinstein M, Kleinstiver BP, Sousa AA, Joung JK, Crawford J, Gao K, Hoang L, Elibol M, Doench JG, Fusi N. (2018) Predicting off-target effects in silico for end-to-end CRISPR guide RNA design. Nature Biomedical Engineering; 2: 38-47

  21. Tak ET, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK. (2017) Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. Nature Methods; 14(12):1163-1166

This guy hasn’t plasmids anything yet.

Hot plasmids

This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2021 MolecularCloud